152 related articles for article (PubMed ID: 19321084)
1. [Hematology: experiences with common national reports on new anti-cancer drugs].
Kristensen JS; Bukh A
Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
[No Abstract] [Full Text] [Related]
2. [Clinical trials and studies of the German Society for Paediatric Oncology and Haematology (GPOH) and the European Directive for the Implementation of Good Clinical Practice in the Conduct of Clinical Trials].
Graf N; Göbel U
Klin Padiatr; 2004; 216(3):129-31. PubMed ID: 15175956
[No Abstract] [Full Text] [Related]
3. Wanted: guidelines for "palliative" anti-cancer drug use.
Kearsley JH
Med J Aust; 1994 Jun; 160(11):723-5. PubMed ID: 7515460
[No Abstract] [Full Text] [Related]
4. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
Rukavitsyn OA; Pop VP
Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
[No Abstract] [Full Text] [Related]
5. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
6. New drug development.
Cheson BD
Clin Adv Hematol Oncol; 2009 Sep; 7(9):556. PubMed ID: 20020666
[No Abstract] [Full Text] [Related]
7. [Costs of cancer chemotherapy].
Kjaer M
Ugeskr Laeger; 1994 Jan; 156(4):449-50. PubMed ID: 8140659
[No Abstract] [Full Text] [Related]
8. [Ambulatory chemotherapy in hematology. A challenge ...].
Montagne C; Duran B
Soins; 1996 Sep; (608):62-8. PubMed ID: 8954491
[No Abstract] [Full Text] [Related]
9. Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
Bennett CL; Tigue CC; Angelotta C; McKoy JM; Edwards BJ
Semin Thromb Hemost; 2007 Jun; 33(4):365-72. PubMed ID: 17525894
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of children and adolecents with cancer after the application of the guide lines for good clinical practice in 2004 and the evaluation of new measurements].
Göbel U; Körholz D; Bernig T; Niehues T; Klingebiel T; Eggert A
Klin Padiatr; 2012 Oct; 224(6):335-8. PubMed ID: 23143760
[No Abstract] [Full Text] [Related]
11. [Antineoplastic agents and biologic response modifiers in oncologic hematology].
Cabrera Marín JR; Briz del Blanco M
Rev Clin Esp; 1999 Apr; 199 Suppl 1():3-13. PubMed ID: 10422445
[No Abstract] [Full Text] [Related]
12. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
13. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
Mailankody S; Prasad V
JAMA Oncol; 2015 Jul; 1(4):539-40. PubMed ID: 26181265
[No Abstract] [Full Text] [Related]
14. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.
Whittington MD; McQueen RB; Campbell JD
JAMA Pediatr; 2018 May; 172(5):409-410. PubMed ID: 29554182
[No Abstract] [Full Text] [Related]
15. Pricing and Value of Cancer Drugs.
Burkholder R
JAMA Oncol; 2015 Sep; 1(6):841-2. PubMed ID: 26355865
[No Abstract] [Full Text] [Related]
16. Pricing and Value of Cancer Drugs--Reply.
Mailankody S; Prasad V
JAMA Oncol; 2015 Sep; 1(6):842-3. PubMed ID: 26355867
[No Abstract] [Full Text] [Related]
17. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
18. [Research on demethylation therapy for hematology malignancy].
Shen JZ; Zhou HR
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):355-6. PubMed ID: 16780731
[No Abstract] [Full Text] [Related]
19. [A role of new molecular-target drugs for hematologic malignancies].
Usui N
Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
[No Abstract] [Full Text] [Related]
20. Soaring price of cancer drugs leads plans to new approaches.
Sipkoff M
Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
